Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F18%3A00011914" target="_blank" >RIV/00023736:_____/18:00011914 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00106196 RIV/65269705:_____/18:00069499
Result on the web
<a href="https://doi.org/10.3324/haematol.2017.171884" target="_blank" >https://doi.org/10.3324/haematol.2017.171884</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2017.171884" target="_blank" >10.3324/haematol.2017.171884</a>

Result language
angličtina
Original language name
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
Original language description
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that patients develop oxidant-mediated tissue injury through the formation of toxic iron species, caused either by red blood cell transfusions or by ineffective erythropoiesis. We analyzed serum samples from 100 lower-risk patients with myelodysplastic syndromes at six-month intervals for transferrin saturation, hepcidin-25, growth differentiation factor 15, soluble transferrin receptor, non-transferrin bound iron and labile plasma iron in order to evaluate temporal changes in iron metabolism and the presence of potentially toxic iron species and their impact on survival.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)